biostudies-literatureUnknown2(4)Lawrence MN<h4>Introduction</h4>Remote consent and enrollment offer a unique opportunity to provide rare cancer populations with access to clinical research. The genomic analysis of plasma cell-free DNA (cfDNA) permits remote characterization of the cancer genome. We hypothesized we could leverage these approaches to remotely study drug resistance in patients with metastatic <i>ALK</i>-positive NSCLC.<h4>Methods</h4>The SPACEWALK study (Study of Plasma Next-Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients With ALK Drug Resistance) enrolled patients with <i>ALK</i>-positive NSCLC and progression on a next-generation ALK inhibitor who could participate remotely. Plasma was collected for next-generation sequencing (NGS) of cfDNA before initiating subsequent therapy, JTO clinical and research reports100151https://www.ebi.ac.uk/biostudies/studies/S-EPMC8474207biostudies-literatureSPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping.PMC8474207Barbour PHosseini SAMartinez PHong FMichael KSimon GRShaffer TBertucci CAwad MMAddario TRiess JWOxnard GRTamen RMSable-Hunt ALawrence MNLim LPfalseSPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping.<h4>Introduction</h4>Remote consent and enrollment offer a unique opportunity to provide rare cancer populations with access to clinical research. The genomic analysis of plasma cell-free DNA (cfDNA) permits remote characterization of the cancer genome. We hypothesized we could leverage these approaches to remotely study drug resistance in patients with metastatic <i>ALK</i>-positive NSCLC.<h4>Methods</h4>The SPACEWALK study (Study of Plasma Next-Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients With ALK Drug Resistance) enrolled patients with <i>ALK</i>-positive NSCLC and progression on a next-generation ALK inhibitor who could participate remotely. Plasma was collected for next-generation sequencing (NGS) of cfDNA before initiating subsequent therapy, 2021-01-01T00:00:00Z2021 Apr2025-04-18T14:26:32.161Z2022-02-11T11:37:08.112ZS-EPMC84742073459000810.1016/j.jtocrr.2021.100151